Eagle Pharma Outsourcing, LLC: FDA NDC listings
Does Eagle Pharma Outsourcing, LLC list GLP-1 drug products with FDA?
Yes. FDA’s NDC Directory files, read Nov 15, 2026, list 2 products naming semaglutide under the labeler name “Eagle Pharma Outsourcing, LLC”, in these marketing categories: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (2). A listing is the labeler’s own submission; FDA says it does not indicate that FDA has verified the information or that the product is FDA-approved.
- GLP-1 listings
- 2
- Marketing categories
- OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (2)
- Drugs named
- Semaglutide
This page exists because the labeler has 2 or more compounded or bulk ingredient GLP-1 listings in FDA’s NDC files and no other page here under the same name. FDA’s NDC files give a labeler name, not an address or FEI number, so this index has not tied this labeler to any FDA inspection, letter or import record.
Listings
| Reporting periods | ||||||||
|---|---|---|---|---|---|---|---|---|
| 69852-417 | Semaglutide 1 mg/mL | Semaglutide 1 mg/mL | INJECTION, SOLUTION | SUBCUTANEOUS | 1 mg/1 mg | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 | Compounded drugs |
| 69852-517 | Semaglutide 2.4 mg/mL | Semaglutide 2.4 mg/mL | INJECTION, SOLUTION | SUBCUTANEOUS | 2.4 mg/2.4 mg | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 | Compounded drugs |
FDA: “Outsourcing facilities that have elected to assign NDCs to their products provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year.”
FDA’s own words on the NDC Directory page (content current as of Mar 4, 2026):
Inclusion in the NDC Directory does not indicate that FDA has verified the information provided or that the products are FDA-approved. The content of each NDC Directory entry is the responsibility of the labeler submitting the SPL file. Assignment of an NDC number does not in any way denote FDA approval of the product. Any representation that creates an impression of FDA approval because a product has an NDC number is misleading and violates federal law. Inclusion in the NDC Directory or assignment of an NDC number does not mean a product is a drug as defined by federal law.
This page restates listings from FDA’s NDC Directory files as FDA publishes them. A listing is the labeler’s own submission to FDA, not an FDA approval and not a finding by this site, and it says nothing about inspections or enforcement. Follow the source link for FDA’s files. Report an error or add a company response.
Sources
- FDA National Drug Code Directory (download files)
- FDA: NDC product file definitions
- openFDA drug NDC endpoint (count cross-check)
Records last pulled Nov 15, 2026. Every entry links to the original public record.